Eli Lilly and Company

Arvind L Thakkar

Philip J Burck

Ronald E Zimmerman

Lowell L Gibson

C David Jones

Stephanie Ann Sweetana

Kerry John Hartauer

Julian L Stowers

George J Cullinan

Henry U Bryant

Roger G Harrison

David E Magee

Paul C Francis

George William Cuff

Amorphous benzothiophenes, methods of preparation and methods of use

This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.

Solid orally administerable raloxifene hydrochloride pharmaceutical

This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.

The present invention provides aqueous inclusion complexes of certain known benzothiophene compounds, particularly Raloxifene, and water soluble cyclodextrins. Also provided are pharmaceutical compositions of such inclusion complexes, and methods of using these complexes for inhibiting bone loss and reducing serum cholesterol in mammals.

Aqueous solution inclusion complexes of benzothiophene compounds with

This invention provides orally administerable pharmaceutical formulations having a semi-solid matrix containing a hydrophilic substance capable of creating channels in a hydrophobic carrier matrix thereby providing a sustained rate of release of an active agent from the formulation.

Orally administerable sustained release pharmaceutical formulation

Orally administerable sustained release pharmaceutical formulations

This invention provides injectable semi-solid formulations comprising a pharmaceutically or veterinary active agent, an oil and a suitable glyceride release modifying agent.

Injectable semi-solid formulations

Long chain alkyl and alkenyl sulfonates, sulfates and sulfoalkyl alkanoate salts, administered intravaginally for contraception.

Contraceptive methods

Stable polymorphic crystalline form of trans-dl-1-hydroxy-3-(1',1'-dimethylheptyl)-6,6-dimethyl-6,6a,7,8,-10,10a- hexahydro-9H-dibenzo[b,d]pyran-9-one, capable of producing significant blood levels in mammals for long periods of time after oral administration of the drug.

Novel polymorphic crystalline form of dibenzopyranone

Introduction of a pharmaceutically acceptable non-toxic cation salt of a straight-chain or branched chain alkyl sulfonate having from 11 to 16 carbon atoms into the uterine lumen or vaginal cavity prevents conception. Sodium tetradecyl sulfonate is preferred.

Contraceptive methods and compositions

Introduction of a pharmaceutically acceptable non-toxic cation salt of a sulfoalkyl alkanoate, for example, sodium sulfopropyl dodecanoate, into the uterine lumen or vaginal cavity prevents conception.

Introduction of a compound of the formula:

Introduction of a pharmaceutically acceptable non-toxic cation salt of a sterol sulfate into the uterine lumen or vaginal cavity prevents conception. Potassium or pyridinium .beta.-sitosteryl sulfate is preferred.

Novel A-32390:PVP compositions useful in the treatment of fungal infections.

Growing community of inventors

Indianapolis, IN, United States of America

Arvind L Thakkar